Hemcheck Sweden AB and Siemens Healthcare A/S (Siemens Healthineers) have entered into a collaboration agreement focused on the blood gas market in the Nordics. The agreement is set for an initial period of 18 months and focused on a selected number of customer accounts. The ambition is to deliver a unique combined solution to customers, offering blood gas analysis with hemolysis detection, which is not available in the market today. There are no revenue commitments linked to this agreement.
“It is both gratifying and exciting that Hemcheck, can enter into a collaboration with a world-leading player such as Siemens Healthineers. Together we will be able to deliver a unique solution to the blood gas market in the Nordic countries. Our published scientific studies have already shown that hemolysis is common also in blood gas samples and that it is an important source of error that can negatively impact patient safety. The fact that Siemens Healthineers wants to work with us in order to win contracts and new customers in this market is of course very positive. We see our collaboration as an important step on the road to make our vision of hemolysis-free blood sampling real. It will enable faster progress in the market and thus pave the way for a more secure and efficient healthcare”, says Hemcheck’s CEO Joen Averstad.
Blood gas analysis are routinely performed at hospitals, but can, just as blood samples analysed at laboratories, be affected by hemolysis. The blood gas analysis equipment available on the market today does not control blood gas samples for hemolysis. In 2018 Hemcheck conducted a clinical study with the aim of mapping the hemolysis rate in blood gas samples taken at an emergency unit and was then able to show that the hemolysis rate was about 8 percent.
The Swedish blood gas market is estimated to approximately three million blood gas tests, of which approximately one million blood gas samples are taken at emergency care units. Over 500 million blood gas tests are conducted globally every year.
For further information, please contact
Hemcheck Sweden AB (publ)
Joen Averstad, CEO
Tel +46 (0) 76 108 8191
About Siemens Healthineers
Siemens Healthineers is a global leading medical technology company with approximately 50,000 employees in over 70 countries. Siemens Healthineers is one of the largest players in the global blood gas market. The company is listed on the Frankfurt Stock Exchange with Siemens AG as majority owner. For further information, please visit https://www.siemens-healthineers.com/se/.
Hemcheck Sweden AB, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. The concept consists of disposable tests as well as readers that enable, directly upon sampling, identification of hemolysed blood samples in vacuum tubes and blood gas syringes. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower healthcare costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.
FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company
This information is such information that Hemcheck is required to disclose in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, for publication by the above contact person, for publication on December 10, 2019 at 23.15